Objectives To evaluate in twin pregnancy the utility of non-invasive prenatal testing using circulating cell-free fetal DNA (cfDNA) 
INTRODUCTION
Increased use of fertility treatment and advanced maternal age are responsible for the increased prevalence of twin pregnancy, which is around 3% in the USA. Screening for trisomy 21 in twins relies on nuchal translucency measurement in the first trimester and maternal age, though some patients are offered firstand second-trimester screening. These approaches have sensitivities of 80% for nuchal translucency and maternal age alone and 86% for combined screening, with a high false-positive rate (4-10%) [1] [2] [3] , especially in cases of pregnancy conceived after assisted reproductive technology (ART) 4, 5 . This false-positive rate leads to unnecessary invasive procedures, with a theoretically higher rate of induced miscarriage than for singletons 6, 7 . First evaluated in a high-risk population, cell-free fetal DNA (cfDNA) testing could be used as a primary screening option after the first-trimester scan. Its use has spread, although recommendations may vary from one country to another; the recommendations for multiple pregnancies, in particular, are unclear because of a lack of sufficient data [8] [9] [10] [11] . Indeed, only eight prospective studies have been reported to date on the use of cfDNA in twin pregnancies (Table 1) 12-19 , but they show high specificity and positive predictive values for trisomy 21 screening. The main drawback in most studies is the high percentage of 'no-results', which ranges from 0.9% to 13.2%, and could Table 1 Prospective studies on use of cell-free DNA analysis in twin pregnancy for trisomy 21 (T21) screening Only first author's name is given. limit the use of some assays in clinical practice. In a recent meta-analysis, Gil et al. 20 concluded that trisomy-21 screening in twin pregnancies is encouraging, but that the number of reported cases is small. The International Society of Ultrasound in Obstetrics and Gynecology has updated its consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice, stating that 'Accuracy of cfDNA testing in twin pregnancies should be investigated further' 21 . Although some cfDNA technologies can potentially provide information on how many fetuses are affected in cases of dichorionic pregnancy 22 , invasive sampling of both twins is still recommended when there is a positive result. Notwithstanding this, in view of the highly encouraging results obtained by our group using cfDNA testing in singletons 23 , we decided to offer cfDNA screening for trisomies 21, 18 and 13 to patients with a twin pregnancy as first-line screening or after maternal serum screening in the absence of ultrasound abnormality on the first-trimester scan. Here we report the performance of the cfDNA assay in the detection of the three main autosomal fetal trisomies (21, 18 and 13) in twin pregnancies in a clinical setting.
METHODS
cfDNA analysis was offered, as part of routine clinical practice, as a screening test for trisomies 21, 18 and 13 to patients with a twin pregnancy, and the results were used to guide their management. Written informed consent was obtained from all patients, as usually required by French regulations on prenatal testing. Cerba Laboratory is authorized by the Regional Health Agency to perform these screening tests.
In order to evaluate the performance of our assay, 492 twin pregnancies with no abnormal fetal ultrasound finding and with nuchal translucency < 3.5 mm were recruited from 1 November 2013 to 31 August 2015. Data were collected prospectively and analyzed retrospectively. All women underwent a first-trimester ultrasound scan with nuchal translucency measurement. As first-trimester serum screening for twins is not recommended in France, the women had cfDNA screening immediately after the first-trimester ultrasound (n = 377) or as a second-line test after second-trimester maternal serum screening (n = 115). In the latter group, at least one of the fetuses had a calculated risk of ≥ 1/250 in 106 cases and a risk of between 1/251 and 1/1000 in nine cases. All patients were more than 10 weeks pregnant. The cfDNA assay was assessed by comparing the reported results with the fetal karyotype obtained when an invasive procedure was performed, or with clinical examination by pediatricians of the newborns at birth.
cfDNA analysis in maternal plasma
cfDNA analysis was performed by massively parallel sequencing using a whole-genome approach, as described elsewhere, with slight modifications 24 . Maternal blood was collected in two cfDNA BCT tubes (Streck ® , La Vista, NE, USA) (10 mL for each) and sent at +4
• C to the clinical laboratory, where plasma was isolated within 4 days after collection by a double centrifugation procedure and stored frozen at ≤ -70
• C if not processed immediately. Total DNA was extracted from 4 mL of plasma using the QIAamp DSP Circulating Nucleic Acid Kit (Qiagen, Courtaboeuf, France) and the DNA libraries were then prepared starting from 50 μL of extracted DNA solution by using the TruSeq DNA Sample Prep reagents (Illumina, Paris, France) or the NEBNext Ultra DNA Library Prep Kit (NEB, Evry, France). After quantification on the LabChip GX microfluidic platform (Perkin-Elmer, Courtaboeuf, France), the libraries from 12 different samples were pooled and sequenced on each lane of an Illumina V3 flow-cell on a HiSeq1500 instrument with the Truseq SBS kit V3-HS reagent (Illumina, Paris, France) for 27 cycles followed by seven or eight cycles to read each sample index. Finally, sequence reads were mapped to the UCSC hg19 version of the human genome using Bowtie version 2 (Johns Hopkins University, Baltimore, MD, USA). As described previously, Z-scores were calculated for the targeted chromosomes (13, 18 and 21) and classification was based upon a standard normal transformed cut-off value of Z = 3 for chromosome 21 and Z = 3.95 for chromosomes 18 and 13 24 . As part of the assay, the fetal fraction estimate was evaluated using the sequence read approach (SeqFF) described by Kim et al. 25 . This 'non-fetal-specific' method is based on a multivariate regression model and on subtle fragment-length differences in, and the inferred non-uniformity of, cfDNA across the genome, so it does not determine the contributions of individual twin fetuses, but the sum of both.
Results are expressed as 'positive' or 'negative' when the metric criteria (total count of reads should be ≥ 9 million and the estimated fetal DNA fraction ≥ 8%) are fulfilled and 'no-result' if they are not. The latter metric is of particular importance, as it might influence test performance based on counting methods. A theoretical value of 8% was used whatever the chorionicity, assuming that each fetus contributes adequate amounts of DNA to the maternal plasma to ensure accurate results, compared with the 4% value validated previously for use in singleton pregnancies.
Statistical analysis
Descriptive results are reported as percentages for categorical variables and as median and range for quantitative variables. The performance of the test was characterized by specificity and sensitivity. Exact 95% CIs were computed with the binomial distribution. Percentages were compared using the chi-square or Fisher's exact test, and the Mann-Whitney U-test was used to compare medians.
Univariate analysis was used to investigate the effect of chorionicity (monochorionic, dichorionic) on test failure rate at first sampling and pregnancy outcome (with trisomy 21/18 or 13 (yes, no)), and method of conception (ART, spontaneous) as categorical variables, and on maternal age (years), weight (kg) and gestational age at test (weeks) as continuous numerical variables. Multiple logistic regression analysis was performed subsequently to determine the significant independent contribution of those variables yielding a P-value of < 0.1 in the univariate analysis.
Data were analyzed using the statistical software SPSS, version 24.0 (SPSS, Chicago, IL, USA), and Excel version 9.0 (Microsoft Corp., Redmond, WA, USA); two-sided P < 0.05 was considered to be statistically significant.
RESULTS
Overall, 492 patients were included. Chorionicity was determined for all but four patients on the first-trimester scan, with 387 (78.7%) pregnancies being dichorionic (DC) and 101 (20.5%) monochorionic (MC) (97 (19.7%) monochorionic-diamniotic (MC-DA), 4 (0.8%) monochorionic-monoamniotic (MC-MA)). Pregnancies were conceived spontaneously in 301 (61.2%) cases and resulted from ART in 184 (37.4%), either by in-vitro fertilization (IVF) (n = 109), IVF-intracytoplasmic sperm injection (IVF-ICSI) (n = 38) or egg donation (n = 37); no data were available for seven patients (1.4%). Intrauterine inseminations were excluded from the analysis.
Median maternal age was 37 years (range, 19-49 years) and median maternal weight at sampling was 63 kg (range, 43-110 kg). Of the 492 patients, 64.0% (n = 315) were more than 35 years old and 9.6% (n = 47) had a body mass index (BMI) ≥ 30 kg/m 2 . Median gestational age at sampling for cfDNA screening was 16.3 weeks (range, 10.2-35.5 weeks). Median fetal fraction was 13.4% (range, 4.6-30.2%).
Fifty-nine (12.0%) patients were lost to follow-up, and no karyotype could be obtained for 13 (2.6%) pregnancies. Therefore, cfDNA screening could be assessed for 420 patients for whom neonatal clinical data and/or fetal karyotypes were available. The demographic and pregnancy characteristics of these patients are reported in Table 2 . Of the 158 (37.6%) of these pregnancies conceived by ART, 95 (60.1%) were by IVF, 36 (22.8%) by IVF-ICSI and 27 (17.1%) by egg donation. Of the 86 (20.5%) MC pregnancies, 82 (95.3%) were MC-DA and four (4.7%) were MC-MA.
cfDNA testing did not provide results from the first sample obtained from the patients in 12 of the 420 (2.9%) twin pregnancies because of insufficient fetal fraction (n = 11; 2.6%) or atypical Z-score (n = 1; 0.2%). Univariate regression analysis demonstrated that significant predictors of failure of the test were pregnancy outcome with trisomy 21, 18 or 13 and higher maternal weight. Multivariate regression analysis demonstrated that only maternal weight was a significant independent predictor of test failure (Table 2) . Of these 12 pregnancies, nine were DC-DA and three were MC-DA. Median gestational age was 15.1 weeks (range, 12.1-21.5 weeks) and median BMI was 32.4 kg/m (range, 19.5-37.5 kg/m 2 ). The patient with atypical results had a spontaneous miscarriage at 19 + 6 weeks and thus could not be further assessed. Ten out of these 12 patients were tested for a second time, and all tests yielded a successful result, one of them being trisomy 13. Thus, the final no-result rate observed in the study after re-sampling was 0.5% (2/420). One of the two patients with no result delivered an unaffected fetus prematurely at 20 weeks' gestation, while the second delivered a clinically unaffected newborn prematurely at 31 weeks.
Overall, cfDNA screening was positive for trisomy 21 in four cases, for trisomy 18 in one case and for trisomy 13 in one case, and negative for all others (Figure 1 ). Among the positive results reported for trisomy 21, one was a false positive. For this case, blood sampling was performed at 14.2 weeks and fetal fraction was 14.4%, with a Z-score of 3.2; BMI was 28.1 kg/m 2 and the pregnancy was MC-DA. Amniocentesis performed on both amniotic fluids revealed normal karyotypes, and the mother delivered two healthy babies at term. The placental tissues could not be explored. For the three other patients (DC-DA pregnancies), invasive procedures confirmed that one of the two fetuses was affected and the pregnancy was terminated selectively. Therefore, overall specificity For trisomies 18 and 13, sensitivity and specificity could not be calculated because of the low number of cases. The fetus with trisomy 18 was diagnosed at 15 weeks in a DC-DA pregnancy without any typical ultrasound findings, and was then terminated selectively after the diagnosis was confirmed. One patient (DC-DA pregnancy) was positive for trisomy 13 with no ultrasound abnormality. The patient declined invasive sampling and gave birth to two healthy children, though one was growth restricted; they weighed 2910 g and 1784 g at 34 + 5 weeks. The karyotypes of both babies were normal, but a positive quantitative polymerase chain reaction result for chromosome 13 was found by analysis of DNA extracted from the placenta of the growth-restricted fetus. Among patients for whom a negative cfDNA assay was reported (n = 414), no fetuses or newborns were affected by trisomies 13, 18 or 21.
Amniocentesis was performed in 10 cases because of a fetal anomaly on the follow-up scan (n = 2), abnormal second-trimester maternal serum screening findings and the mother not being reassured by normal cfDNA test findings (n = 3) or in order to confirm a positive non-invasive prenatal test (n = 5).
When considering whether pregnancies were conceived spontaneously or after ART, there were significant differences in terms of maternal age, gestational age at cfDNA testing and fetal fraction; however, there was no significant difference in maternal weight or no-result rate between the two groups (Table 3) . No intrauterine insemination cases, which did not include egg manipulation, were included. Similarly, no difference was noted with regard to whether cfDNA assay was performed as primary screening (n = 318) or as a second-line test for patients at high risk (n = 94) after maternal biochemical screening (eight patients were at low risk after serum screening and agreed to cfDNA testing).
DISCUSSION
There are three options for trisomy-21 screening in twin pregnancy: nuchal translucency measurement combined with maternal age, with or without biochemical markers measured in the first or second trimester, and cfDNA screening.
The performance of second-trimester biochemical screening in twins is considered to be relatively poor 1 . The introduction of biochemical markers in addition to nuchal translucency and maternal age during the first trimester in a combined screening approach led to an improvement in the detection rate of trisomy 21 in dizygotic twins from 78% to 90%, while the false-positive rate decreased from 8% to 5.9% 2 . Nevertheless, screening for trisomy 21 in twins is possibly responsible for an unnecessary increase in the number of invasive procedures. This is especially problematic in the context of ART, as 18.7% of women delivering twins had an ART procedure 26 . A few studies have suggested that pregnancy-associated plasma protein-A level is lower in ART pregnancies and β-human chorionic gonadotropin (β-hCG) is higher in egg donation 5, 27 , and that ART might therefore have a negative impact on biochemical screening, leading to a higher rate of false-positive diagnoses.
Eight prospective studies to date have reported the use of cfDNA in twin pregnancies [12] [13] [14] [15] [16] [17] [18] [19] . Their main characteristics and results are summarized in Table 1 . Overall, even though as many as five different assays are described, based on massively parallel sequencing (targeted 12, 15, 17 or not), the results are excellent in terms of specificity. None of these studies (or the current one) was designed to evaluate sensitivity.
The main difference between studies relates to the no-result percentage, which varies from 0.5% to 13.2%. There are various possible reasons for these discrepancies. The first is that it depends on the way the authors calculated their no-result rate after first or second sampling. This point is not clear in most publications, while the clinical implications of the requirement for a second sample could be important, especially in countries in which timing is critical if termination of pregnancy has to be considered. In our study, the no-result rate was very low, being 12/420 (2.9%) and 2/420 (0.5%) at initial sampling and after resampling, respectively. Although a definitive conclusion cannot be reached regarding whether or not the cfDNA analysis technique has an influence on this rate, it seems that the targeted massively parallel sequencing approach leads to a higher no-result rate. Sarno et al. 17 reported a failed test in 9.4% of cases after the first sampling and in 4.8% after the second. This difference could be due not only to the method used for fetal fraction measurement, but also to gestational age at sampling, as discussed below.
Fetal fraction measurement is still debated; some laboratories do not measure routinely fetal fraction, but produce a higher number of reads by deeper sequencing to compensate for, and to minimize the possibility of, false-negative results, but Jensen et al. 24 have demonstrated the hazardous results of this technique. In order to minimize the false-negative rate, other providers use an algorithm that relies on the lower fetal fraction of both twins and includes a quality metric in addition to the low fetal fraction, thereby producing additional failures due to high variation in cfDNA counts 17, 28 . It has been shown that the total fetal fraction could be up to 35% higher in twin pregnancies than in singleton pregnancies 29 , but the fetal fraction per twin is lower in some studies 15, 17 and higher in others at a similar gestational age 18 , and it has also been found that the contributions from each twin could differ by as much as two-fold 22, 30 . The method used in our study is global for both fetuses and cannot be used to assess their individual contribution. The 8% threshold value for a negative result assumes that the contribution of each fetus to the plasma cfDNA is enough to ensure accurate results, even if it is not known whether each fetus contributed adequate amounts of DNA. This point is of importance, as 79% of included twins were DC-DA, but this should not affect the results in DC-MA pregnancies owing to the method of measurement used in our study, and emphasizes the need for the lab to evaluate its method before pursuing cfDNA analysis in multiple pregnancies.
The second reason for between-study differences relates to the mean gestational age at sampling for fetal-fraction measurement. In our study, as well as in the study by Fosler et al. 18 , mean gestational age was 16 weeks. Other studies are needed to ensure that early screening does not result in a higher no-result rate. New generations of assays, including both fetal-fraction measurement and sequencing depth in a single dynamic algorithm, should avoid this 31 . Conventional biochemical screening is not appropriate in cases of egg donation, as β-hCG is higher in such pregnancies than in the control group 5 . Therefore, a reliable cfDNA test is of particular interest for these patients. Our method was compatible with ART pregnancies, including egg donation, whereas cfDNA assays based on SNP-counting are not.
Bevilacqua et al. 15 and Sarno et al. 17 showed that, in twin pregnancies, conception by IVF provided significant independent prediction of test failure. Tan et al. 16 recently showed that, in 565 twin pregnancies resulting from ART, the failure rate was low (0.9%), with a 100% positive-predictive value for trisomy 21, even though this study did not include a control group of twin pregnancies without an ART procedure. We found no difference in test performance between the ART and the spontaneous-conception groups. The no-result rate was the same in both groups. Although the two groups differed in age and fetal fraction, logistic regression analysis for the prediction of failure of cfDNA testing in twins showed that only maternal weight significantly influenced it.
The strengths of our study are that we evaluated cfDNA screening in a clinical interventional setting and we report a lower no-result rate. Our data highlight the need to provide patients with a twin pregnancy with clear and comprehensive information on screening for the main aneuploidies. Pending larger prospective first-trimester studies, screening for trisomy 21 using cfDNA assay can be offered in twin pregnancies as a first-line screening test, early in the second trimester.
